荃信生物JKN2401注射液启动III期临床 适应症为中重度慢性阻塞性肺疾病

新浪财经
Dec 30, 2025

药物临床试验登记与信息公示平台数据显示,江苏荃信生物医药股份有限公司的一项评价皮下注射JKN2401注射液治疗中、重度慢性阻塞性肺疾病(COPD)有效性、安全性的随机、双盲、安慰剂对照III期临床研究已启动。临床试验登记号为CTR20255170,首次公示信息日期为2025年12月30日。该药物剂型为注射液,用法为皮下注射,用量为560mg,每4周给药一次,共给药13次。本次试验主要目的为评价...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10